Cure CMT
Cure CMT
Cure CMT is a venture philanthropy organization. That means we do more than fund research. We invest directly in the companies building treatments for Charcot-Marie-Tooth disease and the peripheral nerve disorders connected to it.
Every investment decision runs through Cure CMT’s CURES Team (Capital Uniting Research and Evaluation Strategy), our internal scientific and diligence committee. CURES evaluates each opportunity on scientific rationale, development feasibility, and alignment with our patient-centered priorities: speed, rigor, oversight, and impact.
We’re not looking for safe bets. We’re looking for programs with a sound mechanistic foundation and a credible, near-term path to helping patients.
BXQ-350 for metastatic colorectal cancer and chemotherapy-induced peripheral neuropathy
Our investment supports continued development of BXQ-350, which has shown encouraging early results in metastatic colorectal cancer and in reducing nerve damage caused by chemotherapy. Peripheral neuropathy from cancer treatment shares biology with CMT, making this a direct line to our mission.
A precision medicine platform for CMT, built to serve the whole field
This investment funds a first-of-its-kind isogenic iPSC and AI-modeling platform spanning multiple genetically defined CMT subtypes. Beyond accelerating ReviR’s lead candidate RTX-117, the platform is designed to become a shared, openly accessible resource for researchers and biotech companies working on CMT worldwide.
A small molecule program for CMT1A
EverTree Bio is advancing a therapeutic program targeting CMT1A, the most common form of the disease. Our investment helps move this program from concept toward the clinic, backed by CURES Team diligence on the underlying science and the strength of EverTree’s team.
Vectorized RNAi therapeutics for neurological and neuromuscular disease
Armatus Bio is a preclinical biotech company developing gene-silencing therapies delivered through advanced vector technology. Their platform targets the disease-causing genes behind conditions like CMT that have historically had no therapeutic options. This investment closed out 2025 and reflects our continued push into earlier-stage science with long-term promise.